Crist, R C
Doyle, G A
Nelson, E C
Degenhardt, L
Martin, N G
Montgomery, G W
Saxon, A J
Ling, W
Berrettini, W H
Article History
Received: 25 August 2016
Revised: 7 November 2016
Accepted: 14 November 2016
First Online: 13 December 2016
Competing interests
: Dr Degenhardt has received educational grants from Mundipharma International and Indivior Dr Saxon receives funding from MedicaSafe and has received compensation from UpToDate, Indivior and Alkermes. Dr Ling is a consultant for Indivior, US WorldMed and Cerecor and also has research support from the Patient-Centered Outcomes Research Institute, Indivior, Alkermes and Brauburn Pharmaceuticals. The remaining authors declare no conflict of interest.